---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-23-000009"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:41:42.630096+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Recursion reports FY2022 net loss $239.5M; cash $549.9M; pipeline advances

## Summary
- Net loss of $239.5M for FY2022, up from $186.5M in FY2021; Q4 net loss $57.5M.
- Revenue of $39.8M (FY2022) vs $10.2M prior year, driven by Roche-Genentech collaboration.
- Cash, cash equivalents and investments $549.9M as of Dec 31, 2022, up from $516.6M.
- Initiated five clinical trials in 2022; expects top-line data for REC-994 (CCM) in 2H 2024 and REC-3964 (C. diff) safety/PK data in 2H 2023.
- Released RxRx3 open-source cellular imaging dataset and MolRec application in January 2023.

## SEC filing metadata
- accession: 0001601830-23-000009
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000009/0001601830-23-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000009/rxrx-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-23-000009
- JSON: https://secwatch.observer/filing/0001601830-23-000009.json
- Plain text: https://secwatch.observer/filing/0001601830-23-000009.txt

## Key facts
- Earnings Releases
  RECURSION PHARMACEUTICALS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On February 27, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000009/0001601830-23-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.